Antiplatelet therapy and drug-eluting stents
February 1, 2014
Is 3 months of dual antiplatelet therapy enough after a drug-eluting stent? Researchers attempted to find out in a trial of more than 3100 patients with stable coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) with a zotarolimus-eluting stent. Patients were then prescribed aspirin (100-200 mg daily) with clopidogrel (Plavix, 75 mg daily) for 3 months or 12 months with roughly the same number of patients in each group. The primary endpoint was net adverse clinical and cerebral events, including all-cause death, myocardial infarction, stroke, or major bleeding, with the secondary endpoint of major cardiac events. The primary outcome rate was the same in each group (P = 0.002 for noninferiority). Cardiac event rate was 8.3% in the short-term group and 7.4% in the long-term group (hazard ratio, 1.12; 95% confidence interval, 0.87-1.45). More importantly between 91 and 360 days (after stopping clopidogrel in the short-term group), the primary outcome was identical between the two groups at 2.6%. The authors conclude that in patients with stable CAD who were treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months with regard to major clinical events and without a significantly higher risk of stent thrombosis (JAMA 2013;310:2510-2522). Larger studies are needed to definitively change the duration of therapy; however, this study offers some comfort for those PCI patients who need to stop clopidogrel early due to bleeding or surgery.
You have reached your article limit for the month. Subscribe now to access this article plus other member-only content.
- Award-winning Medical Content
- Latest Advances & Development in Medicine
- Unbiased Content